Details of the Drug | DrugMAP

General Information of Drug (ID: DMEBZ0Y)

Drug Name

PR-924

Indication

Disease Entry	ICD 11	Status	REF
T lymphoblastic leukaemia	2B33.4	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C37H38N4O5
Canonical SMILES: CC1=C(CC2=CC=CC=C12)C(=O)NC(C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC5=CC=CC=C5)C(=O)C6(CO6)C
InChI: 1S/C37H38N4O5/c1-22-27-14-8-7-13-25(27)18-29(22)35(44)39-23(2)34(43)41-32(19-26-20-38-30-16-10-9-15-28(26)30)36(45)40-31(33(42)37(3)21-46-37)17-24-11-5-4-6-12-24/h4-16,20,23,31-32,38H,17-19,21H2,1-3H3,(H,39,44)(H,40,45)(H,41,43)/t23-,31+,32+,37-/m1/s1
InChIKey: ADBUEVSHEJICCM-LZNHGOJSSA-N

Cross-matching ID

PubChem CID: 92135659
CAS Number: 1416709-79-9
TTD ID: D0DP0J

References

1	PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan;152(2):155-63.